RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Efavirenz-Based Therapy Effective in Highly Suppressed HIV-1–Infected Patients
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 48
SP 20
OP 21
DO 10.1177/1559897715590998
UL http://mdc.sagepub.com/content/15/48/20.abstract
AB In the ADVANZ-3 trial, among patients with advanced HIV-1, 96 weeks of daily combination treatment with efavirenz plus tenofovir/emtricitabine is as effective in increasing CD4+ T-cell levels as daily combination treatment using atazanavir/ritonavir plus tenofovir/emtricitabine or lopinavir/ritonavir plus tenofovir/emtricitabine. Similar improvements are also seen for inflammation, coagulation, and bacterial translocation markers.